The Science Behind MyoStrain®
The MyoHealth® Score
MyoStrain® software reports MyoHealth® Score, a single, quantitative diagnostic of the percentage of ventricular segments with normal intramyocardial contraction function.
This diafnostic score simplifies complex global calues cardiac data into a clinically actionable metric of heart health, allowing physicians to:
• Stratify cardiovascular risk across all heart failure stages (ACC/AHA A–D; NYHA I–IV).
• Stratify risk of cardiotoxicity from cancer treatments from baseline and monitor cardioprotection through cancer care, establish a baseline functional profile for longitudinal follow-up.
• Objectively monitor disease progression, therapeutic response, and myocardial functional recovery.
The MyoHealth® Score categorizes patients according to the percentage of normally contracting myocardium, enabling functional risk stratification across the entire heart failure continuum:
Myocardial performance is within normal limits. No specific action is required based on current evidence. This result serves as a baseline for future comparison. Routine cardiovascular follow-up can be performed annually or every few years, according to clinical context and risk factors.
Indicates a mild to moderate reduction in myocardial performance. Follow-up evaluation is recommended. This MyoHealth Score may be associated with the impact of traditional risk factors and chronic diseases that can lead to an increased risk of cardiovascular disease. Clinical management may include modification of risk factors and implementing appropriate medical management to treat chronic diseases. Periodic reassessment is advised to monitor the progression and response to treatment.
Represents a significant reduction in myocardial function. A comprehensive cardiac assessment is recommended to identify underlying causes and establish a management plan. Referral to a specialist or multidisciplinary cardiovascular team should be considered to guide treatment, surveillance, and potential therapeutic interventions.
G. Korosoglou, S. Giusca, M. Montenbruck, A. R. Patel, T. Lapinskas, C. Gotze, V. Zieschang, S. Al Tabatabaee, B. Pieske, A. Florian, J. Erley, H. A. Katus, S. Kelle and H. Steen, “Fast strain-encoded cardiac magnetic resonance for diagnostic classification and risk stratification of heart failure patients,”
JACC: Cardiovascular Imaging, 4 Jan 2021.
January 11, 2024
Cardiac magnetic resonance (CMR) is the gold standard for the diagnostic classification and risk stratification in most patients with cardiac disorders. The aim of the present study was to investigate the ability of Strain-encoded MR (SENC) for the prediction of major adverse cardiovascular events (MACE).
June 15, 2021
Circulation: Cardiovascular Imaging
This publication features key outcome data from the PREFECT study demonstrating MyoStrain’s ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
January 13, 2021
JACC Cardiovascular Imaging
This article demonstrates MyoStrain’s ability to identify patients with subclinical LV dysfunction and those at risk for heart failure-related outcomes compared with LVEF, providing an additional diagnostic window for prevention treatments.
January 11, 2024
Korosoglou, G. et al.
May 13, 2022
Pezel, T. et al.
January 13, 2021
Korosoglou, G. et al.
This study showed that the percentage of normal myocardium determined by Fast-SENC was a stronger independent predictor of heart failure stages than LVEF, and importantly reclassified 37% of apparently healthy patients as having subclinical LV dysfunction, with those patients showing significantly higher rates of mortality and hospitalisation